Answers are grounded in this paper and cite their sources.
We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance associated with the mesenchymal phenotype.
No takes yet. Share an insight, caveat, or question.
Byers et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: